|
Report Date : |
20.07.2013 |
IDENTIFICATION DETAILS
|
Name : |
DONG-A ST CO., LTD. |
|
|
|
|
Registered Office : |
64, Cheonho-daero, Dongdaemun-gu, Seoul, Korea 130-823 |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Financials (as on) : |
31.03.2013 |
|
|
|
|
Date of Incorporation : |
01.03.2013 |
|
|
|
|
Com. Reg. No.: |
204-86-40122 |
|
|
|
|
Legal Form : |
Listed Company |
|
|
|
|
Line of Business : |
Wholesale of Medical, Precision and Scientific Instruments
and Equipment |
|
|
|
|
No. of Employees : |
1,539 |
RATING & COMMENTS
|
MIRA’s Rating : |
NB |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
-- |
NB |
New Business |
-- |
|
Status : |
New Company |
|
Payment Behaviour : |
Unknown |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SOUTH KOREA - ECONOMIC OVERVIEW
South Korea over the past four decades has demonstrated incredible
growth and global integration to become a high-tech industrialized economy. In
the 1960s, GDP per capita was comparable with levels in the poorer countries of
Africa and Asia. In 2004, South Korea joined the trillion dollar club of world
economies, and is currently the world's 12th largest economy. Initially, a
system of close government and business ties, including directed credit and
import restrictions, made this success possible. The government promoted the
import of raw materials and technology at the expense of consumer goods, and
encouraged savings and investment over consumption. The Asian financial crisis
of 1997-98 exposed longstanding weaknesses in South Korea's development model
including high debt/equity ratios and massive short-term foreign borrowing. GDP
plunged by 6.9% in 1998, and then recovered by 9% in 1999-2000. Korea adopted
numerous economic reforms following the crisis, including greater openness to
foreign investment and imports. Growth moderated to about 4% annually between
2003 and 2007. Korea''s export focused economy was hit hard by the 2008 global
economic downturn, but quickly rebounded in subsequent years, reaching 6.3%
growth in 2010. The US-South Korea Free Trade Agreement was ratified by both
governments in 2011 and went into effect in March 2012. Throughout 2012 the
economy experienced sluggish growth because of market slowdowns in the United
States, China, and the Eurozone. The incoming administration in 2013, following
the December 2012 presidential election, is likely to face the challenges of
balancing heavy reliance on exports with developing domestic-oriented sectors,
such as services. The South Korean economy''s long term challenges include a
rapidly aging population, inflexible labor market, and heavy reliance on
exports - which comprise half of GDP.
Source
: CIA
|
Company
Name |
DONG-A ST CO.,
LTD. (Korean Company
Name : “동아에스티(주)”) |
|
Registered Address |
64,
Cheonho-daero, Dongdaemun-gu, Seoul, Korea |
|
Zip Code |
130-823 |
|
Tel |
+82-2-920-8114 |
|
Fax |
+82-2-925-4026 |
|
E-mail |
scshin@donga.co.kr |
|
Website |
www.donga.co.kr |
|
Trading Address |
252, Yongdu-dong, Dongdaemun-gu, Seoul,
Korea |
|
Tel |
+82-2-920-8114 |
|
Fax |
+82-2-925-4026 |
|
Type |
Import |
|
Industry |
Manufacture of Finished Medicaments |
|
Main Business |
Robustness Internal Medicine, Synthesis Cold Medicine, Dyeing
Medicine, Dyeing Medicine |
|
Sub
Business |
Wholesale of Medical, Precision and Scientific Instruments and
Equipment |
|
Established (mm/dd/yyyy) |
03/01/2013 |
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Antiulcer and related gastrointestinal GI drugs(51171900) |
|
Sell |
Thrombolytic drugs and platelet aggregation inhibitors(51131700) |
|
Sell |
Lip balm(53131630) |
|
Sell |
Dietary supplements and nutritional therapy products(51191900) |
|
Sell |
Clinical and diagnostic analyzer reagents(41116000) |
|
Sell |
Cough and cold and antiallergy products(51161800) |
|
Sell |
Antifungal drugs(51101800) |
|
Name |
Kim Won-Bae |
|
Date of Birth |
08/1947 |
|
Title |
Vice Chairman & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
35,007,940,000 |
||||||||||||||||||||||||
|
Employees |
1,539 |
||||||||||||||||||||||||
|
Formation |
Listed Company(Koreas Stock Exchange : 170900) as of 04/08/2013 A Company of Dong-A Socio Group |
||||||||||||||||||||||||
|
Bank Details |
Woori Bank-Shinsul Dong Branch |
||||||||||||||||||||||||
|
Corporate Registered No. |
110111-5079713 |
||||||||||||||||||||||||
|
Business Registered No. |
204-86-40122 |
||||||||||||||||||||||||
|
Permit & Licenses |
Int’l Trade No.: 671484 |
||||||||||||||||||||||||
|
Shareholder Position |
|
||||||||||||||||||||||||
|
Company History |
03/01/2013 Incorporated as the present name after split off from DONG-A
PHARMACEUTICAL CO., LTD.(110111-0017990) |
||||||||||||||||||||||||
|
|
|
|
Job Description |
Title |
Name |
Nationality |
Date of Birth |
Education |
|
Vice Chairman & CEO |
Mr. |
Kim Won-Bae |
Korean |
1947.08 |
Seoul National University, Korea |
|
President & CEO |
Mr. |
Park Chan-Il |
Korean |
1955.09 |
Seoul National University, Korea |
|
Sr. Executive Director |
Mr. |
Hur Jung-Koo |
Korean |
1957.03 |
Chungang University, Korea |
|
Outside Director |
Mr. |
Kim Keun-Soo |
Korean |
1963.06 |
New York State University, USA |
|
Outside Director |
Mr. |
Kim Dae-Kyung |
Korean |
1955.04 |
Tokyo University, Japan |
|
Outside Director |
Mr. |
Seo Young-Je |
Korean |
1950.01 |
Sungkyunkwan University, Korea |
|
Director |
Mr. |
Kang Jung-Seok |
Korean |
1964.01 |
Sungkyunkwan University, Korea |
|
Director |
Mr. |
You Chung-Shik |
Korean |
1936.07 |
Seoul National University, Korea |
|
Director |
Mr. |
Kim Jin-Ho |
Korean |
1950.03 |
Columbia University, Korea |
|
Auditor |
Mr. |
Jang Seung-Duck |
Korean |
1969.04 |
Korea University, Korea |
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
47,910,111,026 |
982,732,431,026 |
-88,333,286,670 |
|
Authorized Capital(KRW) |
150,000,000,000 |
|
Paid-Up Capital(KRW) |
35,007,940,000 |
|
Total Issued Shares |
7,701,936(Common : 7,001,588 / Preferable :700,348) |
Balance
Sheet
|
|||
|
Unit : Korean Won |
01/01/2013~03/31/2013 |
As of 12/31/2012 |
As of 12/31/2011 |
|
Total Assets |
982,732,431,026 |
|
|
|
Current
Assets |
403,361,621,177 |
|
|
|
Cash & Cash Equivalents |
189,235,391,180 |
|
|
|
Trade Receivables |
108,498,079,874 |
|
|
|
Other Receivables |
3,675,033,094 |
|
|
|
Inventories |
95,221,308,783 |
|
|
|
Other Current Assets |
6,731,808,246 |
|
|
|
Non-Current
Assets |
579,370,809,849 |
|
|
|
Deposits |
7,500,000 |
|
|
|
Other Receivables |
2,886,566,928 |
|
|
|
Other Financial Assets |
32,376,381,134 |
|
|
|
Tangibles |
481,360,389,343 |
|
|
|
Intangibles |
9,792,637,288 |
|
|
|
Investment_Real Estates |
52,910,089,447 |
|
|
|
Other Non-Current Assets |
37,245,709 |
|
|
|
Total
Liabilities |
603,194,545,695 |
|
|
|
Current
Liabilities |
335,868,281,131 |
|
|
|
Trade Payables |
27,555,940,647 |
|
|
|
Other Payables |
72,320,280,923 |
|
|
|
Short-Term Borrowings |
169,490,821,126 |
|
|
|
Provisions |
5,894,487,186 |
|
|
|
Other Current Liabilities |
2,954,620,580 |
|
|
|
Deferred Income Tax Credit |
57,652,130,669 |
|
|
|
Non-Current
Liabilities |
267,326,264,564 |
|
|
|
Other Payables |
7,144,571,592 |
|
|
|
Long-Term Borrowings |
216,962,035,898 |
|
|
|
Confirmed Salaries |
16,782,442,983 |
|
|
|
Other Non-Current Liabilities |
5,524,534,741 |
|
|
|
Deferred Income Tax Credit |
20,912,679,350 |
|
|
|
Capital
Stock |
35,007,940,000 |
|
|
|
Capital Surplus |
245,470,113,516 |
|
|
|
Others |
188,356,456,654 |
|
|
|
Profit Surplus |
-89,296,624,839 |
|
|
|
Total Equity |
379,537,885,331 |
|
|
|
Liab. & Shareholder’s Equity |
982,732,431,026 |
|
|
Income
Statement
|
|||
|
Unit : Korean Won |
01/01/2013~03/31/2013 |
As of 12/31/2012 |
As of 12/31/2011 |
|
Sales |
47,910,111,026 |
|
|
|
Cost of Sold Goods |
21,775,398,189 |
|
|
|
Gross Profit |
26,134,712,837 |
|
|
|
Selling & Admin. Expenses |
22,717,242,425 |
|
|
|
Operating Income |
3,417,470,412 |
|
|
|
Other Income |
1,017,402,525 |
|
|
|
Other Expenses |
21,267,406,162 |
|
|
|
Finance Income |
449,925,069 |
|
|
|
Finance Expenses |
3,269,969,897 |
|
|
|
Income Before Taxes |
-19,652,578,053 |
|
|
|
Income Taxes Expenses |
68,680,708,617 |
|
|
|
Net Income |
-88,333,286,670 |
|
|
Cash
Flows
|
|||
|
Unit : Korean Won |
01/01/2013~03/31/2013 |
As of 12/31/2012 |
As of 12/31/2011 |
|
Operating Activities Cash Flows |
-930,095,398 |
|
|
|
Net
Income |
-88,333,286,670 |
|
|
|
Adjustment |
74,822,865,005 |
|
|
|
Changes
in Asset/ & Liability |
27,462,851,967 |
|
|
|
Income
Taxes |
-14,882,525,700 |
|
|
|
Cash Flows from Investing |
-2,797,624,462 |
|
|
|
Cash
Inflow from Investing |
619,749,550 |
|
|
|
Cash
Outflows for Investing |
-3,417,374,012 |
|
|
|
Cash Flows from Financing |
-2,388,410,161 |
|
|
|
Cash Inflows from Financing |
|
|
|
|
Cash
Outflows from Financing |
-2,388,410,161 |
|
|
|
Increase/Decrease in Cash |
-6,116,130,021 |
|
|
|
Cash at the Beginning of Year |
195,278,864,328 |
|
|
|
Cash at the End of Year |
189,235,391,180 |
|
|
|
Main Products & Services |
Robustness Internal Medicine, Synthesis Cold Medicine, Dyeing
Medicine, Dyeing Medicine |
|
Detailed Products Spec. |
|
|
Suppliers |
ST PHARM CO., LTD.(154511-0039704) DONG-A OTSUKA CO., LTD.(134111-0007761) |
|
Competitors |
YUHAN CORPORATION(110111-0014409) 49-6, DAEBANG-DONG, DONGJAK-GU, SEOUL,
KOREA TEL:+82-2-828-0181 FAX:+82-2-828-0050 HANMI PHARM CO., LTD.(110111-0014409) 893-5, HAJEO-RI, PALTAN-MYEON, HWASEONG-SI,
GYEONGGI-DO, KOREA TEL:+82-31-356-3311 FAX:+82-31-356-5151 GREEN CROSS CORPORATION(110111-0109854) 303, BOJEONG-DONG, GIHEUNG-GU, YONGIN-SI,
GYEONGGI-DO, KOREA TEL:+82-31-260-9300 FAX:+82-31-260-9413 |
(Subsidiaries, Joint-Venture & Affiliates)
|
Affiliates |
DONG-A SOCIO HOLDINGS CO., LTD.(110111-0017990) DONG-A OTSUKA CO., LTD.(134111-0007761) YONGMA LOGIS CO., LTD.(110111-0245369) DIGITAL OCEAN CO., LTD.(110111-1574874) SOO-SEOK CO., LTD.(110111-0107973) SOO-SEOK FARM CO., LTD.(164511-0016114) SOOSEOK INDUSTRIAL DEVELOPMENT CO.
LTD.(160111-0117790) DONG-A OTSUKA CO., LTD.(134111-0007761) KOREA SINTO CO., LTD.(130111-0010792) YONGMA LOGIS CO., LTD.(110111-0245369) SOO SEOK TRADING CO., LTD.(110111-0634231) DONG-A PHRAMTEC CO., LTD.(110111-2615578) DA INFORMATION CO., LTD.(110111-3479478) MOPEED CO., LTD.(110111-3372979) ST PHARM CO., LTD.(154511-0039704) JIN-A GLASSES CO. D.A.C MOPEED AP MOPPED PHILIPPINES |
(Activity &
Markets)
Not Available.
No.
--
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.59.79 |
|
|
1 |
Rs.91.03 |
|
Euro |
1 |
Rs.78.52 |
INFORMATION DETAILS
|
Report
Prepared by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.